Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23023340 | 1.00 | CYP1A2 (0.52) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL23640635 | 1.00 | CYP1A2 (0.52) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL88569 | 0.93 | — | — | |
| SCHEMBL254110 | 0.93 | — | — | |
| SCHEMBL96320 | 0.93 | — | — | |
| SCHEMBL28049632 | 0.86 | CHRNB4 (0.47) | CHRNB4CHRNA3 | |
| SCHEMBL18455129 | 0.84 | CYP1A2 (0.46) | CYP1A2CHRNB4CHRNA3 | |
| SCHEMBL23868178 | 0.84 | — | — | |
| SCHEMBL24917922 | 0.84 | — | — | |
| SCHEMBL20715280 | 0.84 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240229063-A1 | TRANSGENIC CORN EVENT ZM_CSM63715 AND METHODS FOR DETECTION AND USES THEREOF | MONSANTO TECHNOLOGY LLC (US) | 2024-07-11 | — | — | US | disclosed |
| WO-2024064080-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2024-03-28 | — | — | WO | disclosed |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | BAYER AKTIENGESELLSCHAFT (DE) | 2024-01-25 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-11874434-B2 | Ophthalmic devices comprising photochromic materials with reactive substituents | JOHNSON & JOHNSON VISION CARE, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| WO-2023173016-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023173017-A1 | KRAS INHIBITORS FOR TREATING DISEASE | BLOSSOMHILL THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-20080225400-A1 | PHOTOCHROMIC MATERIALS AND PHOTOCHROMIC COMPOSITIONS AND ARTICLES INCLUDING THE SAME | TRANSITIONS OPTICAL, INC. (US) | 2008-09-18 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | TRANSITIONS OPTICAL, INC. (US) | 2008-05-01 | — | — | US | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| US-20070278460-A1 | Photochromic materials comprising metallocenyl groups | TRANSITIONS OPTICAL LIMITED (IE) | 2007-12-06 | — | — | US | disclosed |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TRANSITIONS OPTICAL, INC. (US) | 2007-12-06 | — | — | US | disclosed |
| WO-2007115798-A1 | SUBSTITUTED PHENYLPIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR MODULATORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-10-18 | — | — | WO | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CYP1A2 1549/4885CHRNB4 4879/4885CHRNA3 4868/4885 |
| US-20080103301-A1 | PHOTOCHROMIC MATERIALS DEMONSTRATING IMPROVED FADE RATES | PNPO, FLAD1, CRY2 | CYP1A2 159/4885CHRNB4 3300/4885CHRNA3 3454/4885 |
| US-20230339902-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | IKZF1, IKZF3, IKZF2 | CYP1A2 3530/4885CHRNB4 3026/4885CHRNA3 3830/4885 |
| US-20070278461-A1 | PHOTOCHROMIC MATERIALS COMPRISING HALOALKYL GROUPS | TELO2, EYA3, CRY2 | CYP1A2 1176/4885CHRNB4 1166/4885CHRNA3 581/4885 |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | CYP1A2 2070/4885CHRNB4 3178/4885CHRNA3 3598/4885 |
| US-20240025862-A1 | SUBSTITUTED N-PHENYLURACILS AND SALTS THEREOF, AND USE THEREOF AS HERBICIDAL ACTIVE SUBSTANCES | PFAS, DDT, NOTUM | CYP1A2 226/4885CHRNB4 4712/4885CHRNA3 4662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.